PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
KRYS vs. GEHC
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between KRYS and GEHC is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

KRYS vs. GEHC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Krystal Biotech, Inc. (KRYS) and GE HealthCare Technologies Inc. (GEHC). The values are adjusted to include any dividend payments, if applicable.

-30.00%-20.00%-10.00%0.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-31.60%
1.92%
KRYS
GEHC

Key characteristics

Sharpe Ratio

KRYS:

0.24

GEHC:

0.37

Sortino Ratio

KRYS:

0.96

GEHC:

0.70

Omega Ratio

KRYS:

1.11

GEHC:

1.10

Calmar Ratio

KRYS:

0.42

GEHC:

0.52

Martin Ratio

KRYS:

1.10

GEHC:

0.98

Ulcer Index

KRYS:

12.84%

GEHC:

10.72%

Daily Std Dev

KRYS:

58.13%

GEHC:

28.77%

Max Drawdown

KRYS:

-53.42%

GEHC:

-28.04%

Current Drawdown

KRYS:

-33.24%

GEHC:

-10.29%

Fundamentals

Market Cap

KRYS:

$4.10B

GEHC:

$38.44B

EPS

KRYS:

$1.78

GEHC:

$3.65

PE Ratio

KRYS:

80.13

GEHC:

23.05

Total Revenue (TTM)

KRYS:

$199.38M

GEHC:

$14.35B

Gross Profit (TTM)

KRYS:

$182.28M

GEHC:

$5.92B

EBITDA (TTM)

KRYS:

$51.83M

GEHC:

$2.59B

Returns By Period

In the year-to-date period, KRYS achieves a -8.95% return, which is significantly lower than GEHC's 7.65% return.


KRYS

YTD

-8.95%

1M

-12.83%

6M

-31.60%

1Y

11.12%

5Y*

22.34%

10Y*

N/A

GEHC

YTD

7.65%

1M

3.78%

6M

1.92%

1Y

10.61%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

KRYS vs. GEHC — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KRYS
The Risk-Adjusted Performance Rank of KRYS is 6262
Overall Rank
The Sharpe Ratio Rank of KRYS is 5959
Sharpe Ratio Rank
The Sortino Ratio Rank of KRYS is 6262
Sortino Ratio Rank
The Omega Ratio Rank of KRYS is 5959
Omega Ratio Rank
The Calmar Ratio Rank of KRYS is 6868
Calmar Ratio Rank
The Martin Ratio Rank of KRYS is 6262
Martin Ratio Rank

GEHC
The Risk-Adjusted Performance Rank of GEHC is 6161
Overall Rank
The Sharpe Ratio Rank of GEHC is 6363
Sharpe Ratio Rank
The Sortino Ratio Rank of GEHC is 5555
Sortino Ratio Rank
The Omega Ratio Rank of GEHC is 5656
Omega Ratio Rank
The Calmar Ratio Rank of GEHC is 7171
Calmar Ratio Rank
The Martin Ratio Rank of GEHC is 6161
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

KRYS vs. GEHC - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Krystal Biotech, Inc. (KRYS) and GE HealthCare Technologies Inc. (GEHC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for KRYS, currently valued at 0.24, compared to the broader market-2.000.002.000.240.37
The chart of Sortino ratio for KRYS, currently valued at 0.96, compared to the broader market-4.00-2.000.002.004.000.960.70
The chart of Omega ratio for KRYS, currently valued at 1.11, compared to the broader market0.501.001.502.001.111.10
The chart of Calmar ratio for KRYS, currently valued at 0.42, compared to the broader market0.002.004.006.000.420.52
The chart of Martin ratio for KRYS, currently valued at 1.10, compared to the broader market0.0010.0020.001.100.98
KRYS
GEHC

The current KRYS Sharpe Ratio is 0.24, which is lower than the GEHC Sharpe Ratio of 0.37. The chart below compares the historical Sharpe Ratios of KRYS and GEHC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.000.501.001.502.00AugustSeptemberOctoberNovemberDecember2025
0.24
0.37
KRYS
GEHC

Dividends

KRYS vs. GEHC - Dividend Comparison

KRYS has not paid dividends to shareholders, while GEHC's dividend yield for the trailing twelve months is around 0.15%.


TTM20242023
KRYS
Krystal Biotech, Inc.
0.00%0.00%0.00%
GEHC
GE HealthCare Technologies Inc.
0.15%0.15%0.12%

Drawdowns

KRYS vs. GEHC - Drawdown Comparison

The maximum KRYS drawdown since its inception was -53.42%, which is greater than GEHC's maximum drawdown of -28.04%. Use the drawdown chart below to compare losses from any high point for KRYS and GEHC. For additional features, visit the drawdowns tool.


-35.00%-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-33.24%
-10.29%
KRYS
GEHC

Volatility

KRYS vs. GEHC - Volatility Comparison

Krystal Biotech, Inc. (KRYS) has a higher volatility of 14.44% compared to GE HealthCare Technologies Inc. (GEHC) at 7.18%. This indicates that KRYS's price experiences larger fluctuations and is considered to be riskier than GEHC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%16.00%AugustSeptemberOctoberNovemberDecember2025
14.44%
7.18%
KRYS
GEHC

Financials

KRYS vs. GEHC - Financials Comparison

This section allows you to compare key financial metrics between Krystal Biotech, Inc. and GE HealthCare Technologies Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab